Innovative low toxic drug for the treatment of Parkinson's disease on the basis of monoterpenes
||Active until 15.02.2019|
|Profile code: 4214||Technology offer|
Russian scientists from Novosibirsk institute synthesized a highly effective agent for the treatment of Parkinson's disease (PD) based on monoterpenoid that is not inferior to levodopa (traditional treatment of PD) in effectiveness, but is significantly less toxic and procures no significant side effects. The organization is looking for a partner for full-scale development of new high-performance connection and safe drug for the treatment of Parkinson's disease on the basis of the proposed agent.
The drugs currently used in the treatment of Parkinson's disease have limited possibility of prolonged use and a large number of side effects (tachycardia, cardiac arrhythmia, dyskinesia, cognitive impairment, loss of appetite, hallucinations, paranoia, etc.).
Novosibirsk research institute scientists synthesized a carbocyclic compound with high anti-parkinsonian activity, which was proven in experimental models, and is not inferior in effectiveness to levodopa. The research allowed obtaining the information on the mechanism of action of the anti-parkinsonic agent, which indicate that the compound is an agonist of dopaminergic and antagonist of M- cholinergic system. It is shown that a new compound when administered orally, virtually eliminates motor and emotional distress caused by the development of the parkinsonian syndrome. Unlike levodopa, the compound is effective in treating symptomatic Parkinson induced by intake of neuroleptics.
The compound is low in toxicity; its LD50 is 4250 mg/kg, with effective dose of 10-20 mg/kg. The new compound can be synthesized from common natural compounds monoterpenes - verbenone or α- pinene, a turpentine main component, using available reagents and techniques.
A new compound will serve a basis for development of drug for the treatment of Parkinson's disease with a fundamentally new mechanism of action - it combines the properties of a dopamine agonist and anticholinergic drug.
Main offer's advantages
Clinical Research, Trials ; Diseases ; Medical Research ; Pharmaceutical Products / Drugs
Current stage of development
Under development / lab tested
Property right comments
Russian patent granted in 2011
Type of collaboration sought
Technical Co-operation ; Joint Venture Agreement
Russia ; United States ; Ukraine ; Belarus ; Germany ; France
If you are interested in this project, please leave information about yourself here: